StreetAlpha.app
Home › Stocks › FHTX

Foghorn Therapeutics Inc. (FHTX)

$1.83
▲ +2.23%
LAST CLOSE · NOV 17

Foghorn develops cancer drug candidates that target the chromatin regulatory system, which controls how genes are turned on and off. It last closed at $1.83 on Nov 17, up 2.23% on the day. The average 12-month price target from 3 analysts is $4.00 (+118.6% from the last close), with a high of $5.00 and a low of $2.00. Analyst consensus is Buy, based on the latest ratings from 3 firms (2 buy, 1 hold, 0 sell).

AI Auto Pilots
Is FHTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$112.1M
+357.3% vs a year ago
Net income
$9.4M
8.4% margin
EPS (diluted)
$0.09
Free cash flow
−$83.7M
−74.6% margin
Valuation
Market cap
$109.7M
60.0M shares
P/E
20.3
Price over 12 month EPS
Price to sales
1.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$80.3M
At Sep 30
Shareholder equity
−$14.1M
Shares outstanding
60.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.3M$1.3MFY2021FY2022: $19.2M$19.2MFY2022FY2023: $34.2M$34.2MFY2023FY2024: $22.6M$22.6MFY2024FY2025: $30.9M$30.9MFY2025

From FHTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
3firms
2 Buy1 Hold0 Sell
Each firm's latest rating on FHTX in the past 90 days
Average 12-month target
$4.00
▲ 118.6% upside

Based on 3 analysts who set a price target on FHTX in the past 90 days. The average target is $4.00, with a high of $5.00 and a low of $2.00, compared with the last close of $1.83.

Low $2.00Avg $4.00High $5.00
Blue marker: last close $1.83
Highest target$5.00
Average target$4.00
Lowest target$2.00
Latest rating changes
WedbushDowngrade
Oct 2Hold$2
GuggenheimMaintained
Oct 2Buy$5
HC Wainwright & Co.Maintained
Oct 2Buy$5
DateFirmActionRatingPrice target
Oct 2WedbushDowngradeHold$2
Oct 2GuggenheimMaintainedBuy$5
Oct 2HC Wainwright & Co.MaintainedBuy$5
Loading…

Technical Analysis

FHTX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 10% below its 20 day and 46% below its 50 day average. It is 144% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the Pivot at $1.80, and the nearest resistance the Pivot R1 at $1.86.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 10.2%/day
Key levels
$7.6152 week high+315.8%
$4.47200 day average+144.3%
$4.15100 day average+126.8%
$2.6650 day average+45.4%
$2.10Swing high (Oct 21)+14.8%
$2.0220 day average+10.4%
$1.86Pivot R1+1.6%
$1.83Last close
$1.80Pivot−1.6%
$1.80Swing low (Oct 14)−1.6%
$1.77Pivot S1−3.3%
$1.7452 week low−4.9%
Indicators
RSI (14)35.43Weak, oversold below 30Neutral
MACD-0.20Above its signal lineBullish
Stochastic29.3Middle of its rangeNeutral
ADX (14)37.5Trending down
Williams %R-80.8Oversold below −80, overbought above −20Oversold
CCI (20)-204.2Oversold below −100, overbought above 100Oversold
Rate of change−14.1%Change over 10 sessionsBearish
ATR (14)$0.19Typical daily range, 10.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for FHTX

What happened before

See how FHTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow FHTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How FHTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in FHTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

FHTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲72 buying vs 36 selling
  • ▲Held by funds +3.6 pts
  • ▲Funds holding +19
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding122103+18.4%
In funds' top 10220.0%
Held by funds78.6%74.9%+3.6 pts
New / increased29 / 4314 / 39+35.8%
Reduced / sold out26 / 1025 / 14−7.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See FHTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FHTX is in one of them and how their past FHTX trades turned out.

FHTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered FHTX in an article yet. Here's the latest on the wider market.

About Foghorn Therapeutics

Foghorn is a biotechnology company that develops drug candidates for cancer by targeting the chromatin regulatory system, the set of cellular components that control whether genes are switched on or off. Its lead candidate, FHD-909, is an oral medicine that blocks SMARCA2 and is being developed with the pharmaceutical company Eli Lilly. The company's end users are patients with cancer, and it is based in Cambridge, Massachusetts. It uses a proprietary platform called Gene Traffic Control to identify and test new drug targets.

Headquarters
Cambridge, MA